Article Versions Notes

Zhao L, Yu Q, Gao C, Xiang J, Zheng B, Feng Y, Li R, Zhang W, Hong X, Zhan Y-y, et al. Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion. Cancers. 2022; 14(10):2492. https://doi.org/10.3390/cancers14102492

Zhao, Lingying, Qiang Yu, Chunyi Gao, Jingzhou Xiang, Bowen Zheng, Yujie Feng, Runyang Li, Wenqing Zhang, Xiaoting Hong, Yan-yan Zhan, and et al. 2022. "Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion" Cancers 14, no. 10: 2492. https://doi.org/10.3390/cancers14102492

Zhao, L., Yu, Q., Gao, C., Xiang, J., Zheng, B., Feng, Y., Li, R., Zhang, W., Hong, X., Zhan, Y. -y., Xiao, L., & Hu, T. (2022). Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion. Cancers, 14(10), 2492. https://doi.org/10.3390/cancers14102492